Abstract: A semiconductor circuit is disclosed, including a DLL circuit for supplying a desired signal-delay amount. The DLL circuit includes detecting means for detecting variations of a signal-delay amount, and delay-amount control means for generating a delay-amount control signal for controlling, depending on the variations of the signal-delay amount detected by the detecting means, the signal-delay amount of the DLL circuit. The semiconductor circuit further includes a part for monitoring circuit performance of the semiconductor circuit based on the delay-amount control signal.

Abstract: This invention relates to piperazine derivatives of the formula: wherein each symbol is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or preventing Tachykinin-mediated diseases in human being or animals.

Abstract: This invention relates to piperazine derivatives of the formula: wherein each symbol is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or preventing Tachykinin-mediated diseases in human being or animals.

Abstract: The present invention is a compound and pharmaceutical composition comprising a compound of formula (I): 1

Abstract: The present invention is a compound and pharmaceutical composition comprising a compound of formula (I): wherein R1 is a 4-(lower) alkyl-imidazol-1-yl or a 4,5-di(lower) alkyl-imidazol-1-yl group, R2 is a hydrogen atom or a lower alkyl group, and R3 is a fluorenyl group. The compound of formula (I) includes pharmaceutically acceptable salts: The compound of formula (I) and salts thereof have 5-HT antagonism activity.

Abstract: A quinazolinone derivatives having poly (adenosine 5′-diphaspho-ribose)polymerase (PARP) inhibotory activity represented by the formula (I), wherein R1 is optionally substituted cyclic amino groups or optionally substituted amino group, R2 is substituent, n means an integer from 0 to 4, and L is lower akkylene or lower alkenylene, or its prodrug, or their salts.

Abstract: The present invention provides a T cell line carrying a reporter gene that contains an LTR sequence of HIV and expressing CCR5. This T cell line is suitable for use in an efficient screening method for efficiently finding out a medicine such as an anti-HIV agent.

Abstract: This invention relates to piperazine derivatives of formula (I), wherein Y is bond or lower alkylene, R1 is aryl which may have substituent(s), R2 is aryl or indolyl, each of which may have substituent(s), R3 is hydrogen or lower alkyl, and R4 is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or preventing Tachykinin-mediated diseases in human beings or animals.

Abstract: The object of the present invention is to provide a T cell line capable of continuously producing human immunodeficiency virus (HIV) using CC chemokine receptor 5 (CCR5); and being in a state of continuously producing human immunodeficiency virus (HIV) or in a state wherein human immunodeficiency virus (HIV) is latently infecting, and a method for isolating and producing the T cell line.

Abstract: To provide a working vehicle with a simple body structure, an HST case containing a hydraulic stepless transmission is disposed between an engine adjacent one end in a fore and aft direction of a vehicle body, and a propelling transmission case disposed adjacent the other end in the fore and aft direction. The HST case, with the engine and propelling transmission case, forms the vehicle body. With this construction, a driving deck is located at a relatively low level so that the driver may board and alight from the deck with ease. Despite the low level of the deck, the bottom of the vehicle body is at a relatively high level to be free from contact with projections on unleveled terrain. Frame strength may be increased where the HST case is connected between a main clutch housing connected to the rear of the engine and the propelling transmission case.

Abstract: This invention relates to piperazine derivatives of the formula: wherein each symbol is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or Tachykinin-mediated diseases in human beings or animals.

Abstract: A piperazine compound of the formula: ##STR1## wherein: X is carbonyl or sulfonyl;Y is a direct bond or lower alkylene; andR.sub.1, R.sub.2, R.sub.3, R.sub.4 are as defined herein. The compounds are advantageously used as Tachykinin antagonists in the treatment of respiratory diseases, ophthalmic diseases and inflammatory diseases, for example.

Abstract: A non-ionic surfactant represented by the general formula (1) or (2) shown below, an emulsified composition and a dispersion containing same are disclosed. Also disclosed is a method of preparing glycoside compound having nonionic surface active properties. The nonionic surfactant has good safety to human bodies and is excellent in producing foam with good feeling in touch.General formula ?1!:?Z(OH).sub.q-1 !--O?C.sub.3 H.sub.5 (OH)O!--R.sup.1 ?1!wherein ?Z(OH).sub.q-1 ! stands for a saccharide residue excluding the hydroxyl group connected to the carbon atom in anomeric position among q hydroxyl groups connected to the saccharide compound of the formula ?Z(OH).sub.q !, --O?C.sub.3 H.sub.5 (OH)O!-- for a glycerol residue excluding 2 hydrogen atoms from glycerol HO?C.sub.3 H.sub.5 (OH)O!--H, and R.sup.1 for an aliphatic group having 1-12 carbon atoms,General formula ?2!:?Z(OH).sub.q-1 !--O?C.sub.3 H.sub.5 (OH)O!.sub.x --R.sup.2 ?2!wherein ?Z(OH)!.sub.

Abstract: A piperazine compound of the formula: ##STR1## wherein: X is carbonyl or sulfonyl;Y is a direct bond or lower alkylene; andR.sub.1, R.sub.2, R.sub.3, R.sub.4 are as defined herein. The compounds are advantageously used as Tachykinin antagonists in the treatment of respiratory diseases, ophthalmic diseases and inflammatory diseases, for example.

Abstract: A method of making a peptide compound of the formula: ##STR1## wherein R.sup.1 is hydrogen or lower alkyl,R.sup.2 is lower alkyl or halogen,R.sup.3 is hydrogen, lower alkyl or halogen,R.sup.4 is lower alkyl,R.sup.5 is ar(lower)alkyl,R.sup.6 is amino or optionally protected hydroxy, andX is O, S or N--R.sup.7, in which R.sup.7 is N,N-di(lower)alkylamino(lower)alkyl,which is useful as tachykinin antagonist.

Abstract: An ATM exchange which is comprised of a multistage cascade connection of ATM switches of self-routing module structures which are provided with a plurality of outgoing lines and incoming lines, wherein it provides at the output side and the input side of the ATM switches output side conversion interfaces and input side conversion interfaces both for connection of adjoining ATM switches and uses optical cables to connect the output side interfaces and input side interfaces facing thereto. By this, it is possible to maintain the correct exchange operation even if the length of the transfer lines (outgoing lines and incoming lines) laid between ATM switches becomes greater along with extension of the ATM switches in the exchange.

Abstract: A first carrier signal generator (15) generates a carrier signal (S1) at a first frequency to modulate a preset identification code (S). A second carrier signal generator (16) generates a carrier signal (S2) at a second frequency, distinct from the first frequency. A modulator (14) affixes the identification code (S) to the carrier signal (S2), and outputs the carrier signal (S2) to a light-emitting circuit (17). When a "smart" or "learning" remote controller, of the type that demodulates frequency, receives the identification code (S), the carrier signal (Sw) of the second frequency is demodulated at the first frequency, compressed and stored in memory. The carrier signal (S2) set at the second frequency can cause the memory capacity of the remote controller to overflow, thereby preventing the identification code (S) from being stored in the learning remote controller.

Abstract: Disclosed herein are compounds of the following formula: ##STR1## wherein R.sup.1 is a group of the formula ##STR2## "X" is CH.sub.2 or N, "Z" is O, S, or N--R.sup.6, "A" is an amino acid residue, and Y, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are substituent variables as defined herein.The compounds are antagonists of tachykinin, and as such are useful for alleviation of pain and for treatment of disorders including asthma, bronchitis, rhinitis, conjunctivitis, dermatitis, arthritis, and urticaria.

Abstract: A television signal and ATM cell switching system for switching ATM cells of data other than television signals and for supplying one channel among a plurality of channels of television signals transmitted from a source to a subscriber to carry out one-way communication of the television signals from the source to the subscribers and two-way communication of the data other than the television signals between the network and the subscribers comprising, a television signal transmitting unit for transmitting television signals in the form of ATM cells, an ATM switching unit for switching ATM cell data other than the television signals, a television signal cell inserting circuit for receiving a plurality of channels of the television signals from the television signal transmitting unit, and for receiving ATM cell data other than the television signals after being switched by the ATM switching unit, the television signal inserting circuit comprising, a demultiplexing circuit for demultiplexing the output of the AT

Abstract: A compound of the formula: ##STR1## wherein R.sup.1 is aryl, or a group of the formula: ##STR2## wherein X is CH or N, and Z is O or N--R.sup.5,in which R.sup.5 is hydrogen or lower alkyl,R.sup.2 is hydroxy or lower alkoxy,R.sup.3 is hydrogen or lower alkyl which may have suitable substituent(s),R.sup.4 is ar(lower)alkyl which may have suitable substituent(s),A is carbonyl or sulfonyl, andY is a bond or lower alkenylene,and pharmaceutically acceptable salt thereof. The disclosed compounds are useful for treating respiratory diseases such as bronchaedema.